Member Info for RRJ43

Thankyou Ali Mortazavi - what a way to treat small shareholders! Interesting reasoning in the news release as to why they couldn’t garner any interest from UK funds - they’re missing the obvious reason that the. Individuals in charge of those funds are smart and know when a company has zero data and poor scientific leadership to back up waffle around AI! Also something very fishy with Mortazavi, Griffiths and Bretherton - appears the latter’s son is the CFO!! Show s what happens when a CEO has little experience of biology and biotech I guess

Gasman23 - I think you’ll find this is a public forum where individuals can share their opinions- both positive and negative. You don’t happen to work for e-therapeutics, do you?

More words from the company who seem averse to disclosing any hard data! The updates for their haemophilia & cardiometabolic treatments are exactly the same as 6 months ago- so no progress there. If their AI/ML that they stated was “transformative “ back in June they should have multiple new molecules in their pipeline- but no. And a cash burn of ~1M/month for a company with ~30 headcount with nothing substantial to show for it is appalling!

DD77 - I held back on the off-chance Ali would produce something substantial. Unfortunately the data in the interims and in his presentation is poor. Something also doesn’t add up around the timelines for generation of the data - if it was generated in the previous 6 months , where did the data come from in their patent filings back in Feb? Also, during the first 30s of Ali’s presentation he alluded that he had experience with small molecule drug discovery- but there no evidence I can find that he’s ever been involved in this modality? So started to dig into the experience of the C-Suite. CSO appears to have no real DD experience and CBO/COO appears to have followed Ali from Silence. CFO appears to be related to the previous interim CFO. DYOR and you’ll find the reasons to either hold or dump. I know what I’m doing now….

Yep - there was data, both in the interim results and at the interview. Problem is that it’s scant - Alnylam, Arrowhead were all producing comparable data 10 years ago. Where’s the data from animal disease models, tox studies? What have they been doing for the past 2.5 years? If the timeline in Ali’s presentation was realistic they’d have multiple molecules in Ph1 by now. Will wait another 6 months….

Flurry of recent activity means nothing. They’ve produced no new data in 2 years - the data in Ali’s webcast was the last set I’ve seen. If their AI/ML guff was true they’d have something in Phase I by now.

There really wasn’t anything substantial in Ali’s presentation- no data, no scientific results but a lot of jumping on the AI bandwagon. He’s a grifter with virtually no drug discovery experience- I doubt he’s even done an experiment I an actual lab! It’s been at least two years since any preclinical data was disclosed and since then absolutely nothing - no scientific publications, no posters, nothing. Compare to Alnylam 10 years ago who were publishing every couple of months. That speaks volumes. Dumping this stock now